Company Overview of Soleno Therapeutics, Inc.
Key Executives for Soleno Therapeutics, Inc.
|Anish Bhatnagar||11 Relationships||President, CEO, Principal Financial & Accounting Officer and Director||47|
|Jonathan R. Wolter||No Relationships||Interim Chief Financial Officer||67|
|Neil M. Cowen Ph.D., MBA||No Relationships||Senior Vice President of Drug Development||--|
|Anthony Wondka||No Relationships||Senior Vice President of Research & Development||55|
Soleno Therapeutics, Inc. Board Members*
|Name||Board Relationships||Primary Company||Age|
|Ernest Mario||272 Relationships||Apothogen, Inc.||78|
|Anish Bhatnagar||11 Relationships||Soleno Therapeutics, Inc.||47|
|William G. Harris||11 Relationships||Xenoport, Inc.||59|
|Mahendra Gopaldas Shah||58 Relationships||Semnur Pharmaceuticals, Inc.||72|
|James W. Glasheen||39 Relationships||Technology Partners||50|
Soleno Therapeutics, Inc. Executive Committees*
|Committee Name||Chairperson||Board Relationships||Members|
|Audit Committee||William G. Harris||11 Relationships||3 Executives|
|Compensation Committee||Mahendra Gopaldas Shah||58 Relationships||3 Executives|
|Nominating Committee||James W. Glasheen||39 Relationships||3 Executives|
|Corporate Governance Committee||James W. Glasheen||39 Relationships||3 Executives|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
CEO COMPENSATION IN THIS INDUSTRY
|Total Short Term Compensation|
|Total Value of Options||$460.0K|
INDUSTRY EXECUTIVE CHANGES
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.